retatrutide clinical trial news A new from Eli Lilly and Company suggests its experimental triple hormone drug, retatrutide, could become one of the next major medications in the rapidly growing weight loss and diabetes Retatrutide Phase 3 Results: TRIUMPH-1

:- 10

Well review your assessment: One of our healthcare clinicians will go over your assessment to determine the best course of action for your treatment plan, and then theyll contact you to share their recommendations

Some people feel dizzy or anxious

The company has already flagged a US$65 million revenue headwind in Q1 2026 tied to tighter rules around compounded semaglutide shipping, and the Novo Nordisk patent case plus FDA and SEC scrutiny add another layer of uncertainty around how much of this revenue is sustainable and at what margin

Robust clinical evidence supports significant weight loss and cardiometabolic benefits for eligible patients

It has been shown that T4C can act as an intracellular sulfhydryl antioxidant and a scavenger of free radicals and thereby protect cellular membranes and other oxidation-prone structures in the cell from damage due to oxygen and oxygen-derived free radicals (55)